Home › Owlstone Developing Breath Biopsy Tests for Cancer, Asthma as Pharma Services Business Expands

Owlstone Developing Breath Biopsy Tests for Cancer, Asthma as Pharma Services Business Expands

Mar 15, 2018
Premium

NEW YORK (360Dx) – Backed by a fresh round of financing, Owlstone Medical is intensifying its efforts to bring tests for lung cancer, colorectal cancer, and asthma to market on its Breath Biopsy platform in coming years.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
04
Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct
10
Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Canon Medical Systems Acquires Majority Stake in Cancer Genomic Profiling JV

  2. Biocept Plans to Sell $2.5M in Stock, Warrants

  3. Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier

  4. Cancer Genetics, NovellusDx Sign Merger Agreement

  5. Resolution Bioscience Earns NY State Approval for Lung Cancer Liquid Biopsy Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.